Antonio Bustos1, Pablo Selvi Sabater2, María Benlloch3, Eraci Drehmer4, María Mar López-Rodríguez5, Felix Platero6, Jose Luis Platero3, Jesús Escribá-Alepuz7,8, Jose Enrique de la Rubia Ortí3. 1. Physical Therapy Clinic, Antonio Bustos, 46007 Valencia, Spain. 2. Hospital de Riotinto, 21660 Huelva, Spain. 3. Department of Nursing, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain. 4. Department of Basic Sciences, Catholic University of Valencia San Vicente Mártir, 46900 Torrente, Valencia, Spain. 5. Department of Nursing, Physiotherapy and Medicine, University of Almería, 04120 Almería, Spain. 6. Department of Medicine, University of Valencia, 46003 Valencia, Spain. 7. Neurophysiology Department, Sagunto University Hospital, 46520 Valencia, Spain. 8. Institute of Sleep Medicine, 46021 Valencia, Spain.
Abstract
Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated withepigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and clinical associated with the metabolism and functionality) after 4 months of treatment with EGCG are noteworthy. Thus, this treatment is proposed as a good candidate to treat the disease.
RCT Entities:
Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and clinical associated with the metabolism and functionality) after 4 months of treatment with EGCG are noteworthy. Thus, this treatment is proposed as a good candidate to treat the disease.
Entities:
Keywords:
Charcot-Marie-Tooth disease type 2; IL-6; epigallocatechin gallate; motor activity; paraoxonase 1
Authors: S W van den Berg; E H J Jansen; M Kruijshoop; P K Beekhof; E Blaak; C J van der Kallen; M M van Greevenbroek; E J M Feskens Journal: Diabet Med Date: 2008-02 Impact factor: 4.359
Authors: Mariam Chahbouni; María Del Señor López; Antonio Molina-Carballo; Tomás de Haro; Antonio Muñoz-Hoyos; Marisol Fernández-Ortiz; Ana Guerra-Librero; Darío Acuña-Castroviejo Journal: Molecules Date: 2017-10-14 Impact factor: 4.411